SRXH
SRX Global Inc. · AMEX:SRXH
0.9698 USD−0.0402 −3.98%
SRX Global Inc. (AMEX:SRXH) last traded at 0.9698 USD, down 3.98% on the day. Over the past year the stock is down 95.14%. Its 52-week range is 0.8500 to 42.61. It is in the Technology Services sector (Packaged Software).
Key statistics
Open0.9900
Day range0.9415 – 1.08
52-week range0.8500 – 42.61
Volume512.86 K
Average volume (10 days)456.15 K
Market cap19.57 M
Dividend yield0.00%
Beta (1 year)0.9203
Employees11
Performance
−3.02%1 week
−40.14%1 month
−33.12%3 months
−85.77%6 months
−93.09%Year to date
−95.14%1 year
Technical reading
Strongly bearish
Daily summary of what 11 oscillators and 15 moving averages show. See every indicator
Latest headlines
- SRX Global Provides Update on Balance Sheet and Share BuybackGlobeNewswire · 30 Oct 2026
- SRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics’ Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic MalignanciesGlobeNewswire · 26 Oct 2026
- SRX Global, CERO 1236: To Raise Cap Directly Into Subsidiary and Not Dilute Existing SRX Global Hldrs >SRXHDow Jones Newswires · 07 Oct 2026
- SRX Global: Chris Ehrlich and Current CERo Director Brian Atwood Expected to Be on CERo Therapeutics Bd of Directors and Special Advisers to Pres >SRXHDow Jones Newswires · 07 Oct 2026
- SRX Global: Pending Transaction Is Expected to Accelerate the Advancement of CERo's Clinical Programs >SRXHDow Jones Newswires · 07 Oct 2026
- SRX Global: Under the Terms of the Proposed Transaction, Andrew Kucharchuk, Currently CERo Chief Fincl Officer, Is Expected to Be Pres of and Primary Executive of CERo Therapeutics >SRXHDow Jones Newswires · 07 Oct 2026
- SRX Global And CERO 1236, A Wholly-Owned SPV, Enter Into Definitive Agreement To Acquire CERo Therapeutics, An Innovative Cellular Immunotherapy Company Developing CER 1236 For Hematologic Malignancies >SRXHDow Jones Newswires · 07 Oct 2026
- SRX Global Acquires Senior Secured Debt In CERo Therapeutics Holdings, Inc., An Innovative Cellular Immunotherapy Company With Cancer Fighting Molecule For The Treatment Of Hematologic Cancers >SRXHDow Jones Newswires · 31 Aug 2026
Market data is delayed as each exchange requires (see data coverage). SuperCharting is charting software and gives no investment advice.